NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAMS NEWAMSTERDAM PHARMA CO NV

Not Yet Opened 03-31 16:00:00 EDT

20.47

-1.29

-5.93%

盘后20.47

+0.000.00%

16:33 EDT

High22.06	Low19.54	Vol1.52M
Open21.72	D1 Closing21.76	Amplitude11.58%
Mkt Cap2.25B	Tradable Cap1.10B	Total Shares109.82M
T/O31.00M	T/O Rate2.81%	Tradable Shares53.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NAMS","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV","latestPrice":20.47,"timestamp":1743451200000,"preClose":21.76,"halted":0,"volume":1518450,"hourTrading":{"tag":"盘后","latestPrice":20.47,"preClose":20.47,"latestTime":"16:33 EDT","volume":1813,"amount":37113.31,"timestamp":1743453200784},"delay":0,"floatShares":53942717,"shares":109817812,"eps":-2.560438,"marketStatus":"Not Yet Opened","change":-1.29,"latestTime":"03-31 16:00:00 EDT","open":21.72,"high":22.06,"low":19.54,"amount":30995087.304,"amplitude":0.115809,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.560438,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743494400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":21.76,"preHourTrading":{"tag":"盘前","latestPrice":21.65,"preClose":21.76,"latestTime":"07:00 EDT","volume":339,"amount":6252.8495760000005,"timestamp":1743418800413},"postHourTrading":{"tag":"盘后","latestPrice":20.47,"preClose":20.47,"latestTime":"16:33 EDT","volume":1813,"amount":37113.31,"timestamp":1743453200784},"volumeRatio":1.626548,"optionData":{"bulkOrders":[{"symbol":"NAMS","call":true,"expireDate":1747368000000,"strike":"22.5","timestamp":1743437834237,"price":1.45,"volume":2000,"amount":290000,"type":"+"}]},"impliedVol":0.7578,"impliedVolPercentile":0.4629},"requestUrl":"/m/hq/s/NAMS/tweets","defaultTab":"tweets","newsList":[{"id":"2524313138","title":"William Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524313138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524313138?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 10:45","pubTimestamp":1743475508,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today. The company’s shares close...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-keeps-their-buy-rating-on-newamsterdam-pharma-company-nams?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-keeps-their-buy-rating-on-newamsterdam-pharma-company-nams?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAMS"],"gpt_icon":0},{"id":"2523394569","title":"NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2523394569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523394569?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"NAARDEN, the Netherlands and MIAMI, March 31, 2025  -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease  with elevated low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a virtual fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 12:45 p.m. ET.NewAmsterdam Pharma  is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-present-24th-annual-120000808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","NAMS","NAMSW","HCSG"],"gpt_icon":0},{"id":"2516682188","title":"NewAmsterdam Pharma Company Nv : Guggenheim Raises Target Price to $41 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2516682188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516682188?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 19:41","pubTimestamp":1741002063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2516300845","title":"NewAmsterdam Pharma files $500M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300845?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 06:10","pubTimestamp":1740780628,"startTime":"0","endTime":"0","summary":"17:07 EST NewAmsterdam Pharma (NAMS) files $500M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/newamsterdam-pharma-files-500m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/newamsterdam-pharma-files-500m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2514362946","title":"Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514362946","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514362946?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 10:30","pubTimestamp":1740709809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research Report)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-newamsterdam-pharma-company-nams-and-organogenesis-holdings-orgo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-newamsterdam-pharma-company-nams-and-organogenesis-holdings-orgo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","ORGO","BK4139","HCSG","NAMS"],"gpt_icon":0},{"id":"2514082178","title":"NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2514082178","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514082178?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 19:19","pubTimestamp":1740655168,"startTime":"0","endTime":"0","summary":"NasdaqGM:NAMS Earnings and Revenue Growth February 27th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 39%. Earnings per share  missed analyst estimates by 24%.Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 3.7% from a week ago.You should learn about the   3 warning signs  we've spotted with NewAmsterdam Pharma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-full-2024-earnings-111928524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NAMSW","NAMS"],"gpt_icon":0},{"id":"2514874300","title":"NewAmsterdam Pharma Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874300","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874300?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 18:28","pubTimestamp":1740652080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 05:28 ET (10:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS"],"gpt_icon":0},{"id":"2514604842","title":"Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence","url":"https://stock-news.laohu8.com/highlight/detail?id=2514604842","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514604842?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 14:01","pubTimestamp":1740636060,"startTime":"0","endTime":"0","summary":"Newamsterdam Pharma Company N.V. (NAMS) has disclosed a new risk, in the Share Price & Shareholder Rights category. Newamsterdam Pharma Company N.V...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/newamsterdam-pharma-faces-potential-investor-risks-due-to-shareholder-influence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/newamsterdam-pharma-faces-potential-investor-risks-due-to-shareholder-influence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2514864443","title":"NewAmsterdam Pharma Company (NAMS) Receives a Buy from William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514864443","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514864443?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 03:45","pubTimestamp":1740599129,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps reiterated a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today. The company’s shares opene...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/newamsterdam-pharma-company-nams-receives-a-buy-from-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/newamsterdam-pharma-company-nams-receives-a-buy-from-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2514830375","title":"NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2514830375","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514830375?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:26","pubTimestamp":1740576362,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma  reported Wednesday that its full-year 2024 net loss widened to $241.6 million from a net loss of $176.9 million a year earlier.Analysts polled by FactSet expected a loss of $194.5 million.Revenue for full-year 2024 was $45.6 million up from $14.1 million a year earlier.Analysts surveyed by FactSet expected $33.8 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS"],"gpt_icon":0},{"id":"2514837091","title":"Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837091","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837091?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:19","pubTimestamp":1740575981,"startTime":"0","endTime":"0","summary":"Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS"],"gpt_icon":0},{"id":"2514837218","title":"Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Net Loss of $241.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837218","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837218?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:15","pubTimestamp":1740575720,"startTime":"0","endTime":"0","summary":"Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Net Loss of $241.6M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS"],"gpt_icon":0},{"id":"2514083761","title":"NewAmsterdam Pharma FY24 Sales $45.6M Beats $31.982M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514083761","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514083761?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:09","pubTimestamp":1740575380,"startTime":"0","endTime":"0","summary":"Full Year 2024 Financial ResultsCash Position: As of December 31, 2024, NewAmsterdam recorded cash and cash equivalents of $771.7 million and $62.5 million of marketable securities, compared to $340.5 million as of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43971053/newamsterdam-pharma-fy24-sales-45-6m-beats-31-982m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NewAmsterdam Pharma FY24 Sales $45.6M Beats $31.982M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS"],"gpt_icon":0},{"id":"2514283276","title":"Press Release: NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514283276","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514283276?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"-- EMA submission expected in 2H25 by partner Menarini --. -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 --. \"2024 was a transformative year for NewAmsterdam, marked by compelling data from three pivotal Phase 3 trials -- BROOKLYN, TANDEM, and BROADWAY -- where we observed durable LDL-C lowering by obicetrapib for CVD patients. In 2025, we look forward to sharing additional data and insights from these trials, including the impact of obicetrapib on the exploratory endpoint of major adverse cardiac events , at leading medical meetings and journal publications, as well as advancing regulatory interactions, including an anticipated EMA submission in the second half by our partner Menarini,\" said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.-- BROADWAY evaluated obicetrapib in 2,530 adult patients with established","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2514099828","title":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2514099828","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514099828?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025  -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease  with elevated low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:. TD Cowen 45th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4.Leerink Partners Global Healthcare Conference 2025 in Miami, FL on Monday, March 10, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 8:00 a.m. ET.Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-participate-upcoming-investor-130000865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NAMS","BK4139","NAMSW"],"gpt_icon":0},{"id":"2511695490","title":"Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2511695490","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511695490?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 22:01","pubTimestamp":1739541678,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public. A total of 6 investors have a majority stake in the company with 53% ownership. 34% of NewAmsterdam Pharma is held by Institutions. If you want to know who really controls NewAmsterdam Pharma Company N.V. , then you'll have to look at the makeup of its share registry. We can see that private equity firms own the lion's share in the company with 42% ownership. Put another way, the group faces the maximum upside potential .While the holdings of private equity firms took a hit after last week’s 8.1% price drop, institutions with their 34% holdings also suffered.Let's delve deeper into each type of owner of NewAmsterdam Pharma, beginning with the chart below.Check out our latest analysis for NewAmsterdam Pharma. What Does The Institutional Ownership Tell Us About NewAmsterdam Pharma?While it makes sense to study institutional ownership data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/both-private-equity-firms-control-140118208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","NQmain","NAMSW","USAW.SI","TSYW.SI","NDAQ","PSQ","IE00B3QW5Z07.USD","USJW.SI","BK4112","IE00BKPKM429.USD","SQQQ","MNQmain","QID","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","NAMS","QLD","IE00BGHQF748.EUR","NVIW.SI","TQQQ",".IXIC","BK4588"],"gpt_icon":1},{"id":"2509771541","title":"Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509771541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509771541?lang=en_us&edition=full_marsco","pubTime":"2025-02-08 05:20","pubTimestamp":1738963208,"startTime":"0","endTime":"0","summary":"Feb 7 (Reuters) - NewAmsterdam Pharma Company NV ::*NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-FEB-202521:01:00.127 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nRSD5xMDLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2507961169","title":"Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961169","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507961169?lang=en_us&edition=full_marsco","pubTime":"2025-01-31 23:19","pubTimestamp":1738336784,"startTime":"0","endTime":"0","summary":"Novartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2018/04/STOCK-Novartis-02-shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novartis-stock-novartis-earnings-q4-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["SGXZ57979304.SGD","LU2237443978.SGD","LU0061475181.USD","LU0114720955.EUR","LU1127390331.HKD","BK4588","LU0109391861.USD","LU1366192091.USD","LU1988902786.USD","IE0009355771.USD","LU0882574139.USD","LU2089984988.USD","LU0058720904.USD","IE00BK4W5L77.USD","SG9999001176.USD","BK4007","LU0256863902.USD","LU0882574055.USD","BK4566","LLY","LU0096364046.USD","BK4532","LU1057294990.SGD","SG9999001440.SGD","SG9999014880.SGD","IE0002141913.USD","SGXZ31699556.SGD","LU1974910355.USD","IONS","CRSP","LU0256863811.USD","NAMS","LU2491050154.USD","SG9999018865.SGD","SG9999014906.USD","NVS","SG9999014914.USD","LU0354030511.USD","LU2106854487.HKD","LU1989771016.USD","LU0320765059.SGD","LU2361044949.HKD","LU1868837300.USD","LU0238689110.USD","LU2063271972.USD","LU0198837287.USD","SG9999015945.SGD","LU0122379950.USD","SG9999015952.SGD","AMGN"],"gpt_icon":1},{"id":"2507638909","title":"NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507638909","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507638909?lang=en_us&edition=full_marsco","pubTime":"2025-01-29 21:00","pubTimestamp":1738155600,"startTime":"0","endTime":"0","summary":"NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025  -- NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease  with elevated low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.NewAmsterdam Pharma  is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/newamsterdam-pharma-present-guggenheim-smid-130000812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NAMSW","BK4011","SMID","NAMS"],"gpt_icon":0},{"id":"2506251205","title":"NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2506251205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506251205?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 23:04","pubTimestamp":1738076640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2025 10:04 ET (15:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":-0.1471},{"period":"1month","weight":-0.0252},{"period":"3month","weight":-0.2035},{"period":"6month","weight":0.1744},{"period":"1year","weight":-0.1345},{"period":"ytd","weight":-0.2035}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.0166},{"period":"1year","weight":0.0694},{"period":"ytd","weight":-0.0455}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.233023},{"month":2,"riseRate":0.25,"avgChangeRate":0.01095},{"month":3,"riseRate":0.6,"avgChangeRate":-0.001317},{"month":4,"riseRate":0.5,"avgChangeRate":-0.00065},{"month":5,"riseRate":0,"avgChangeRate":-0.047858},{"month":6,"riseRate":0.75,"avgChangeRate":-0.027601},{"month":7,"riseRate":0.25,"avgChangeRate":-0.036015},{"month":8,"riseRate":0.25,"avgChangeRate":-0.035988},{"month":9,"riseRate":0.75,"avgChangeRate":-0.018319},{"month":10,"riseRate":0.5,"avgChangeRate":0.000568},{"month":11,"riseRate":0.5,"avgChangeRate":0.013756},{"month":12,"riseRate":0.75,"avgChangeRate":0.195702}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV","nameEN":"NEWAMSTERDAM PHARMA CO NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEWAMSTERDAM PHARMA CO NV,NAMS,NEWAMSTERDAM PHARMA CO NV股票,NEWAMSTERDAM PHARMA CO NV股票老虎,NEWAMSTERDAM PHARMA CO NV股票老虎国际,NEWAMSTERDAM PHARMA CO NV行情,NEWAMSTERDAM PHARMA CO NV股票行情,NEWAMSTERDAM PHARMA CO NV股价,NEWAMSTERDAM PHARMA CO NV股市,NEWAMSTERDAM PHARMA CO NV股票价格,NEWAMSTERDAM PHARMA CO NV股票交易,NEWAMSTERDAM PHARMA CO NV股票购买,NEWAMSTERDAM PHARMA CO NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction